|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 270.10 USD | -3.51% |
|
-6.19% | -11.10% |
| 02/06 | BeOne Medicines Solid Tumor Data Boost Confidence in Long-term Growth, RBC Says | MT |
| 02/06 | RBC Raises Price Target on BeOne Medicines to $436 From $425, Keeps Outperform Rating | MT |
Company Valuation: BeOne Medicines AG
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 27,843 | 22,843 | 18,862 | 19,667 | 33,619 | 30,028 | - | - |
| Change | - | -17.96% | -17.43% | 4.27% | 70.94% | -10.68% | - | - |
| Enterprise Value (EV) 1 | 24,097 | 19,511 | 16,564 | 18,058 | 30,091 | 25,954 | 25,000 | 23,202 |
| Change | - | -19.03% | -15.1% | 9.02% | 66.64% | -13.75% | -3.68% | -7.19% |
| P/E ratio | -17.8x | -11.3x | -21.3x | -30.2x | 120x | 40.2x | 28.1x | 20.8x |
| PBR | 4.03x | 5.17x | 5.32x | 5.84x | 7.9x | 5.87x | 4.64x | 3.32x |
| PEG | - | -0.4x | 0.4x | 1.1x | -1x | 0x | 0.7x | 0.6x |
| Capitalization / Revenue | 23.7x | 16.1x | 7.67x | 5.16x | 6.29x | 4.64x | 4.04x | 3.6x |
| EV / Revenue | 20.5x | 13.8x | 6.74x | 4.74x | 5.63x | 4.01x | 3.37x | 2.78x |
| EV / EBITDA | -17.3x | -11.3x | -14.8x | -45.6x | 51.1x | 25.7x | 17.4x | 10.7x |
| EV / EBIT | -16.7x | -10.9x | -13.7x | -31.8x | 67.3x | 30.5x | 20.6x | 13.2x |
| EV / FCF | -15.4x | -10.7x | -9.63x | -28.5x | 32x | 36.4x | 22.7x | 15.3x |
| FCF Yield | -6.48% | -9.34% | -10.4% | -3.51% | 3.13% | 2.74% | 4.4% | 6.55% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -15.23 | -19.43 | -8.45 | -6.12 | 2.53 | 6.723 | 9.604 | 13 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 1,176 | 1,416 | 2,459 | 3,810 | 5,343 | 6,477 | 7,424 | 8,347 |
| EBITDA 1 | -1,392 | -1,723 | -1,120 | -396.4 | 588.8 | 1,009 | 1,434 | 2,167 |
| EBIT 1 | -1,439 | -1,790 | -1,208 | -568.2 | 447.1 | 850.6 | 1,211 | 1,761 |
| Net income 1 | -1,413 | -2,004 | -881.7 | -644.8 | 286.9 | 763.9 | 1,096 | 1,540 |
| Net Debt 1 | -3,746 | -3,332 | -2,297 | -1,609 | -3,528 | -4,074 | -5,028 | -6,826 |
| Reference price 2 | 270.93 | 219.94 | 180.36 | 184.71 | 303.81 | 270.10 | 270.10 | 270.10 |
| Nbr of stocks (in thousands) | 1,02,770 | 1,03,859 | 1,04,578 | 1,06,476 | 1,10,658 | 1,11,174 | - | - |
| Announcement Date | 25/02/22 | 27/02/23 | 26/02/24 | 27/02/25 | 26/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 40.18x | 4.01x | 25.73x | -.--% | 3TCr | |
| 29.32x | 5.21x | 16.14x | 1.12% | 4.27TCr | |
| -18.74x | 284.14x | -16.99x | -.--% | 3.17TCr | |
| 22.28x | 2.56x | 11.07x | -.--% | 3.06TCr | |
| 28.96x | 7.47x | 19.23x | 0.42% | 2.42TCr | |
| 22.57x | 1.96x | 8.6x | 1.18% | 1.32TCr | |
| 26.66x | 4.26x | 19.41x | -.--% | 1.3TCr | |
| -20.79x | 13.58x | -20.21x | -.--% | 1.23TCr | |
| 23.79x | 1.71x | 10.36x | -.--% | 1.14TCr | |
| Average | 17.14x | 36.10x | 8.15x | 0.3% | 2.32TCr | |
| Weighted average by Cap. | 18.68x | 47.25x | 9.38x | 0.35% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- ONC Stock
- Valuation BeOne Medicines AG
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition